Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

JSP_Dilution_Player Feb. 20 at 6:53 PM

$TCRX tute added 1,000,000 shares this week and few catalysts ahead as well. Trading at $1... owner's equity approximately around $1.98 per share.

0 · Reply

Elaine_Shrimp Feb. 20 at 5:47 PM

$TCRX three months already... 😂😂😴😴😴 Drop by and say hi 👋🏻👋🏻

0 · Reply

signaljumper Feb. 19 at 5:47 PM

$TCRX a 1.20 Break and Close above will Trigger a bullish w Formation

0 · Reply

OfficialStocktwitsUser Feb. 19 at 12:59 PM

$TCRX RSI: 45.87, MACD: -0.0338 Vol: 0.08, MA20: 1.03, MA50: 1.04 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OfficialStocktwitsUser Feb. 19 at 2:04 AM

0 · Reply

Deliver1 Feb. 19 at 12:52 AM

$TCRX Latest institutional holdings here: https://www.nasdaq.com/market-activity/stocks/tcrx/institutional-holdings

0 · Reply

JSP_Dilution_Player Feb. 18 at 5:33 PM

$TCRX Nice block

0 · Reply

InvestmentView Feb. 18 at 4:11 PM

$TCRX TScan Therapeutics develops T-cell receptor therapies. Clinical milestones drive valuation. Cash runway defines downside risk.

0 · Reply

SaladMan00 Feb. 14 at 6:11 PM

$TCRX when moon?

0 · Reply

leis5 Feb. 14 at 10:24 AM

$TCRX bought some extra at 0,94 😁

0 · Reply

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Nov 12, 2025, 7:00 AM EST - 3 months ago

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 3 months ago

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 6:30 AM EST - 4 months ago

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Sep 17, 2025, 7:00 AM EDT - 5 months ago

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Sep 3, 2025, 7:00 AM EDT - 6 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2025, 7:00 AM EDT - 6 months ago

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 28, 2025, 7:00 AM EDT - 9 months ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 6, 2025, 7:00 AM EDT - 10 months ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 4:53 PM EDT - 10 months ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Mar 31, 2025, 7:00 AM EDT - 11 months ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 11 months ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mar 7, 2025, 11:31 AM EST - 1 year ago

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 10, 2025, 3:14 AM EST - 1 year ago

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Dec 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 9, 2024, 5:45 PM EST - 1 year ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 5, 2024, 9:15 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Aug 26, 2024, 10:09 AM EDT - 1 year ago

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 12, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Updates to its Board of Directors

May 29, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 24, 2024, 4:05 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 1 year ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 2 years ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 2 years ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 2 years ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 2 years ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Jan 29, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 18, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Jan 4, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Dec 27, 2023, 7:00 PM EST - 2 years ago

TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value

Dec 9, 2023, 12:00 PM EST - 2 years ago

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Dec 7, 2023, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

JSP_Dilution_Player Feb. 20 at 6:53 PM

$TCRX tute added 1,000,000 shares this week and few catalysts ahead as well. Trading at $1... owner's equity approximately around $1.98 per share.

0 · Reply

Elaine_Shrimp Feb. 20 at 5:47 PM

$TCRX three months already... 😂😂😴😴😴 Drop by and say hi 👋🏻👋🏻

0 · Reply

signaljumper Feb. 19 at 5:47 PM

$TCRX a 1.20 Break and Close above will Trigger a bullish w Formation

0 · Reply

OfficialStocktwitsUser Feb. 19 at 12:59 PM

0 · Reply

OfficialStocktwitsUser Feb. 19 at 2:04 AM

0 · Reply

Deliver1 Feb. 19 at 12:52 AM

$TCRX Latest institutional holdings here: https://www.nasdaq.com/market-activity/stocks/tcrx/institutional-holdings

0 · Reply

JSP_Dilution_Player Feb. 18 at 5:33 PM

$TCRX Nice block

0 · Reply

InvestmentView Feb. 18 at 4:11 PM

$TCRX TScan Therapeutics develops T-cell receptor therapies. Clinical milestones drive valuation. Cash runway defines downside risk.

0 · Reply

SaladMan00 Feb. 14 at 6:11 PM

$TCRX when moon?

0 · Reply

leis5 Feb. 14 at 10:24 AM

$TCRX bought some extra at 0,94 😁

0 · Reply

JSP_Dilution_Player Feb. 13 at 4:10 PM

$TCRX bio trading way below its Owner's Equity. Trading at .90s and they should have around $1.98 per share value as of 12/31/25. They should give us update on IND submission during their earnings PR. not much downside at this point.

0 · Reply

GeorgeJonesFan_In_Boston Feb. 13 at 2:45 AM

$TCRX is this toast or is there still hope ?

0 · Reply

JSP_Dilution_Player Feb. 6 at 4:26 PM

$TCRX another bio trading way below its Owner's Equity. Trading at .90s and they should have around $1.98 per share value as of 12/31/25. They are suppose to have news as well. Get this back over $1.00 Tute was adding around this price range abt a month ago.

1 · Reply

JSP_Dilution_Player Feb. 5 at 9:23 PM

$TCRX and $FATE both did round trip. both were up almost 25 to 30%. $TCRX management still sleeping .. wake up

0 · Reply

Deliver1 Feb. 4 at 10:21 PM

$TCRX Congrats to all the cancer survivors/warriors! Thank you to all the researchers trying to cure and improve therapies... and those that have succumbed to cancer may they rest in peace. Stay strong people! https://www.worldcancerday.org/about

0 · Reply

NVDAMillionaire Feb. 4 at 12:31 PM

$TCRX Excellent article that nails exactly where TCRX stands right now. So if you want to update your TCRX knowledge or get acquainted with TCRX, this is a must read. https://everyticker.com/quote/TCRX/analysis/tscan-therapeutics-unlocking-t-cell-precision-in-oncology-s-next-frontier-nasdaq-tcrx

0 · Reply

Deliver1 Feb. 4 at 1:24 AM

$TCRX TScan pipeline: https://www.tscan.com/pipeline/our-pipeline/ - waiting on TSC-101 pivotal trial launch - waiting on TSC-102 IND approvals ( management,,, Hello? are you there? Thank you for your attention to this matter)

0 · Reply

Deliver1 Feb. 4 at 1:01 AM

$TCRX February 2026 Corporate presentation - MUST READ!! https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

0 · Reply

JSP_Dilution_Player Feb. 3 at 8:39 PM

added few more today. catalysts/cash plays $TOVX $FATE $TCRX $VTGN $AZTR

0 · Reply

JSP_Dilution_Player Jan. 28 at 4:31 PM

$TCRX wakeup management. IND was supposed to be in 2nd half of 2025. Now we are in end of Jan. I am expecting IND news by mid Feb if already submitted in 1st week of Jan. Trading way below cash and funds into 2nd half of 2027.

0 · Reply

JSP_Dilution_Player Jan. 27 at 4:40 PM

$TCRX looking better today. let's see if this get over 1.2 this week.

0 · Reply

JSP_Dilution_Player Jan. 25 at 11:26 PM

$FATE $TCRX one of these should pop to 1.5. Both are trading way under cash. TCRX has IND News pending.

0 · Reply

Market Cap	57.32M
Revenue (ttm)	2.82M
Net Income (ttm)	-127.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,521.28%
Debt to Equity Ratio	0.23

Volume	169,900
Avg Vol	531,806
Day's Range	N/A - N/A
Shares Out	56.75M
Stochastic %K	60%
Beta	1.04
Analysts	Strong Sell
Price Target	$6.60